Randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety and tolerability as well as the immunological and clinical efficacy of multiple subcutaneous doses of DiaPep277 [peptide p277] in LADA [latent autoimmune diabetes in adults] subjects

Trial Profile

Randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety and tolerability as well as the immunological and clinical efficacy of multiple subcutaneous doses of DiaPep277 [peptide p277] in LADA [latent autoimmune diabetes in adults] subjects

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Peptide p277 (Primary)
  • Indications Latent autoimmune diabetes in adults
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Sep 2006 Status change
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top